Clinical Trials

Latina patients with breast cancer more given more information more likely to enter clinical trials

Latina patients with breast cancer more given more information more likely to enter clinical trials

Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.

Personalized cellular therapy leads to complete remission in acute lymphoblastic leukemia

By

An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.

Drug targeting glioblastoma to begin clinical trial

By

A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.

New drug for multiple myeloma to begin clinical trial

New drug for multiple myeloma to begin clinical trial

By

A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.

Achieving clinical trial participation through cooperative networks

Achieving clinical trial participation through cooperative networks

By

Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

By

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

PD-L1 a possible immunotherapy target in mesothelioma

By

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone

Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.

Dabrafenib hitting the target in subset of patients with non-small cell lung cancer

By

The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

By

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

Once-weekly breast radiation regimen improves on current treatment

By

An experimental regimen of once-weekly breast irradiation after lumpectomy provides more convenience to patients at less expense, and results in better completion rates of prescribed radiation treatment.

Clinical trial results of nintedanib for HER2-negative breast cancer are promising

By

The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.

Prostate Cancer Prevention Trial identifies men most likely to undergo biopsy

By

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.

Everolimus does not improve overall survival of advanced liver cancer

By

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.

Resistant sarcomas slowed by new therapeutic combination

By

A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.

US Food and Drug Administration fast-tracks novel leukemia therapy

US Food and Drug Administration fast-tracks novel leukemia therapy

An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical Biopsy Safe for Some Patients With Late-Stage Lung Cancer

Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations.

Direct injection treatment of pancreatic cancer shows encouraging results

Direct injection treatment of pancreatic cancer shows encouraging results

Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.

Study demonstrates improved diagnosis and outcomes with LDCT

By

A study using a 5-year LDCT screening protocol showed good adherence and patient survival outcomes in persons at high risk of developing lung cancer.

Developing an innovative online cancer information center

Developing an innovative online cancer information center

By

An increasingly complex environment for cancer care and research highlights the need to streamline access to cancer information, especially clinical trials.

Phase 1 trials begin for first-in-class anticancer drug

By

Clinical trials have begun for PFK-158, a small-molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment

By

Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials

Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll

Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll

By

Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.

Experimental treatment shows early promise for advanced neuroblastoma in children

By

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.

Immunotherapy: A New Hope for NSCLC [Video]

Created by the Society for Immunotherapy of Cancer (SITC), this video follows a sample patient's journey from the diagnosis of NSCLC through the process of learning about cancer immunology.

Risk-assessment approach outlined for biomarker-driven clinical trials

By

A practical risk-management approach for effectively integrating biomarkers into cancer clinical trials has been outlined by a working group.

New experimental drug may be game-changer for acute myeloid leukemia

By

Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.

Experts weigh in on managing elderly patients with NSCLC

By

Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.

Intervention fidelity essential for clinical trials

By By

ANAHEIM, CALIFORNIA—Intervention fidelity is an essential element of randomized, clinical trials. To illustrate this point, one researcher described how intervention fidelity was incorporated into her clinical trial evaluating self-administration of acupressure for persistent cancer-related fatigue in breast cancer.

PD-L1 protein levels predict response to immunotherapy in lung cancer patients

By

Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs